$PCRX News

Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly

Viatris to acquire Pacira BioSciences for $1.65 billion

Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?

HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?

Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout

Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal

Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion

Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout

Needham Downgrades Pacira BioSciences to Hold

Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday

Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31

Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home